Vir Biotechnology price target raised to $15 from $12 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Vir Biotechnology to $15 from $12 and keeps an Equal Weight rating on the shares. The firm said that updated preliminary results from the phase 2 SOLSTICE study in hepatitis delta confirm “robust and durable” antiviral activity, while importantly, rates of alanine aminotransferase normalization improved.